These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25126238)

  • 1. The NCCN Compendium for Cancer Management.
    Interview with Bill McGivney, PhD
    Am Health Drug Benefits; 2008 Jun; 1(5):40-4. PubMed ID: 25126238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary report: the development of the NCCN Comparative Therapeutic Index™ as a clinical evaluative process for existing data in oncology.
    Li EC; DeMartino J
    J Natl Compr Canc Netw; 2010 Aug; 8 Suppl 5():S1-9. PubMed ID: 20870621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the Clinical Utility of Biomarkers in Oncology: The NCCN Biomarkers Compendium.
    Birkeland ML; McClure JS
    Arch Pathol Lab Med; 2015 May; 139(5):608-11. PubMed ID: 25333835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compendia and anticancer therapy under Medicare.
    Tillman K; Burton B; Jacques LB; Phurrough SE
    Ann Intern Med; 2009 Mar; 150(5):348-50. PubMed ID: 19221368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.
    Kaa K
    J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S19-26. PubMed ID: 17713991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Clinical Compendia Used for Medicare Part D Coverage Determinations for Off-label Prescribing in Dermatology.
    Barbieri JS; St Claire K; Mostaghimi A; Albrecht J
    JAMA Dermatol; 2019 Mar; 155(3):315-320. PubMed ID: 30673082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review: reliability of compendia methods for off-label oncology indications.
    Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
    Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Comprehensive Cancer Network Guidelines: Who Makes Them? What Are They? Why Are They Important?
    Pluchino LA; D'Amico TA
    Ann Thorac Surg; 2020 Dec; 110(6):1789-1795. PubMed ID: 32298647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer.
    Boland GM; Chang GJ; Haynes AB; Chiang YJ; Chagpar R; Xing Y; Hu CY; Feig BW; You YN; Cormier JN
    Cancer; 2013 Apr; 119(8):1593-601. PubMed ID: 23280510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the National Comprehensive Cancer Network and European Society for Medical Oncology Nasopharyngeal Carcinoma Surveillance Guidelines.
    Zhou GQ; Lv JW; Tang LL; Mao YP; Guo R; Ma J; Sun Y
    Front Oncol; 2020; 10():119. PubMed ID: 32117766
    [No Abstract]   [Full Text] [Related]  

  • 12. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009.
    Xu Y; Liu H; Chen J; Zhou Q
    Thorac Cancer; 2010 Jul; 1(2):83-86. PubMed ID: 27755782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for psychosocial distress: a national survey of oncologists.
    Pirl WF; Muriel A; Hwang V; Kornblith A; Greer J; Donelan K; Greenberg DB; Temel J; Schapira L
    J Support Oncol; 2007; 5(10):499-504. PubMed ID: 18240673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Government and private insurance medical programs as well as MDVIP, an update.
    Edlich RF; Winters KL; Brit LD; Long WB
    J Long Term Eff Med Implants; 2004; 14(3):243-50. PubMed ID: 15301667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare coverage for erythropoiesis-stimulating agents: the perfect storm.
    Interview (Part 1) with Samuel M. Silver, MD, PhD
    Am Health Drug Benefits; 2008 May; 1(4):46-50. PubMed ID: 25126232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
    J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centers for Medicare and Medicaid Services conducts a medical evidence development and coverage advisory committee meeting on carotid atherosclerosis.
    Cambria RP
    J Vasc Surg; 2012 Jul; 56(1):e1-16. PubMed ID: 22749277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managed approaches to multiple sclerosis in special populations.
    Sperandeo K; Nogrady L; Moreo K; Prostko CR
    J Manag Care Pharm; 2011; 17(9 Suppl C):S1-19; quiz S20-1. PubMed ID: 22107156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Implementation of NCCN Guidelines for Distress Management by NCCN Member Institutions.
    Donovan KA; Deshields TL; Corbett C; Riba MB
    J Natl Compr Canc Netw; 2019 Oct; 17(10):1251-1256. PubMed ID: 31590156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.